4-Antibody appoints Dr. Richard Mason as new Chief Executive Officer
4-Antibody AG announced that Dr. Richard Mason has joined the company as Chief Executive Officer and Geschäftsführer. Dr. Mason joins 4-Antibody from venture capital firm Advent Venture Partners, an investor in 4-Antibody, where he has been an Executive-in-Residence.
Previously Dr. Mason was Senior Vice President Business Development at Cambridge Antibody Technology plc (CAT). As head of CAT’s business development team he was responsible for numerous transactions with major pharmaceutical and biotechnology companies including leading the negotiation of the original antibody co-discovery and co-development agreement with AstraZeneca which subsequently led to AstraZeneca’s acquisition of CAT for $1.3 billion.
Dr. Mason qualified in medicine from the Medical College of St. Bartholomew’s Hospital, University of London. He trained in internal medicine and is a member of the Royal College of Physicians. He also holds a BSc degree in Immunology from University College London and an MBA from the Judge Business School, University of Cambridge.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
